| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825714 | Clinical Therapeutics | 2013 | 24 Pages |
Abstract
Based on the findings of the studies reported in this review, rivaroxaban is an effective option for the prevention of VTE after orthopedic surgery, stroke prevention for nonvalvular AF, and treatment of VTE. At this time, rivaroxaban cannot be recommended for secondary risk reduction after ACS because of the increased bleeding risk.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Tyan F. PharmD, Valerie PharmD, Sarah A. PharmD,